Systematic review of Dengue Vaccines (CYD-TDV and TAK-003) in children: efficacy, immunogenicity, safety and challenges
DOI:
https://doi.org/10.67485/am0x1630Keywords:
Dengue Vaccine, Children, Systematic review, Efficacy, Immunogenicity, Safety, ChallengesAbstract
Background: Vaccination has emerged as a promising strategy for dengue prevention, with several vaccines undergoing clinical evaluation. This systematic review is aimed to synthesize the current literature on the efficacy, immunogenicity, and safety of dengue vaccines, particularly CYD-TDV (Dengvaxia®) and TAK-003 (Qdenga®) in children.
Methods: PRISMA guidelines were used to guide standard processes for data extraction during a systematic literature search. To find pertinent research published, electronic databases such as PubMed, Medline, Embase, and the Cochrane Library were searched up to 2024. Observational studies, randomized controlled trials, meta-analyses and systematic reviews, focused on children (<18 years of age) were considered eligible for inclusion. The CYD-TDV vaccination and TAK-003 were evaluated for their overall and serotype-specific effectiveness.
Results: Key findings regarding vaccine efficacy, immunogenicity, and safety in children are summarized in this review. CYD-TDV, despite its efficacy in dengue-experienced individuals, long term safety data demonstrated that this vaccine increased the risk of more severe symptoms upon dengue infection in individuals who were dengue-naive and in children <9 years of age. TAK-003 has shown promising results, with an overall efficacy in preventing symptomatic dengue in children and adolescents.
Conclusion: Dengue vaccines represent a promising tool for dengue prevention in children. While vaccine efficacy and safety issues remain, ongoing research and innovation hold promise for the safer and more effective dengue vaccines development.
Downloads
Downloads
Published
Data Availability Statement
Available with authors on request
Issue
Section
License
Copyright (c) 2026 Muhammad Faheem Afzal (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution - You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
